Company profile
Ticker
CELZ
Exchange
CEO
Mr. Timothy Warbington
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
JOLLEY MARKETING INC
SEC CIK
Corporate docs
Subsidiaries
StemSpine Inc. • ImmCelz Inc. • Creative Medical Technologies Inc. • AmnioStem LLC ...
CELZ stock data
Latest filings (excl ownership)
8-K
Amendments to Articles of Incorporation or Bylaws
26 Dec 24
424B3
Prospectus supplement
20 Nov 24
EFFECT
Notice of effectiveness
20 Nov 24
10-Q
2024 Q3
Quarterly report
8 Nov 24
S-1
IPO registration
8 Nov 24
DEF 14A
Definitive proxy
4 Nov 24
PRER14A
Preliminary revised proxy
23 Oct 24
8-K
Creative Medical Technology Holdings Announces Priced At-The-Market Under Nasdaq Rules
23 Oct 24
424B5
Prospectus supplement for primary offering
23 Oct 24
EFFECT
Notice of effectiveness
16 Oct 24
Latest ownership filings
4
Michael H. Finger
20 Feb 25
4
Timothy Warbington
29 Jun 23
SC 13G/A
Markey John
26 May 23
SC 13G
Markey John
1 May 23
4
Timothy Warbington
23 Nov 22
4
Michael H. Finger
29 Sep 22
4
Timothy Warbington
28 Sep 22
4
Timothy Warbington
22 Sep 22
4
Michael H. Finger
14 Jun 22
4
Timothy Warbington
7 Jun 22
Financial summary
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | |||
---|---|---|---|---|---|---|
Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q | |
Cash on hand (at last report) | 6.26 mm | 6.26 mm | 6.26 mm | 6.26 mm | 6.26 mm | 6.26 mm |
Cash burn (monthly) | 403.68 k | (no burn) | 369.89 k | 469.16 k | 328.53 k | 437.23 k |
Cash used (since last report) | 1.92 mm | n/a | 1.75 mm | 2.23 mm | 1.56 mm | 2.07 mm |
Cash remaining | 4.35 mm | n/a | 4.51 mm | 4.03 mm | 4.70 mm | 4.19 mm |
Runway (months of cash) | 10.8 | n/a | 12.2 | 8.6 | 14.3 | 9.6 |
Institutional ownership, Q3 2024
39.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 6 |
Opened positions | 0 |
Closed positions | 5 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 115.65 mm |
Total shares | 697.08 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
CVI Investments | 332.32 k | $0.00 |
L1 Capital Global Opportunities Master Fund | 327.46 k | $724.00 k |
Aaron Wealth Advisors | 19.57 k | $60.67 mm |
Vanguard | 17.63 k | $53.95 mm |
Advisor | 101.00 | $313.00 k |
TD Waterhouse Canada | 1.00 | $3.00 k |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
19 Feb 25 | Michael H. Finger | Common Stock | Sell | Dispose S | No | No | 5.75 | 750 | 4.31 k | 351 |
18 Feb 25 | Michael H. Finger | Common Stock | Sell | Dispose S | No | No | 5 | 750 | 3.75 k | 1,101 |
News
Creative Medical Technology Announces OvaStem Shows 85% Hormonal Improvement, 70% Success; Orphan Drug Designation Filed
19h ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
6d ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
6d ago
Creative Medical Technology Holdings Announces Mid-term Follow-up Study Data Reporting Reduction In Opioid Use By Chronic Lower Back Pain Patients Undergoing Stemspine Procedure Using Allostem
6d ago
Creative Medical Technology Reports One-Year Results For AlloStem Type 2 Diabetes Program
1w ago
Press releases
Creative Medical Technology Holdings Applauds Presidential Initiative to Expand IVF Access, Showcasing OvaStem® Program's Success and Growth Potential
19h ago
Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing StemSpine® Procedure using AlloStem™
6d ago
Creative Medical Technology Reports Positive One-Year Results for AlloStem™ Type 2 Diabetes Program
1w ago
Creative Medical Technology Holdings Expands Collaboration with Greenstone Biosciences to Accelerate iPSCelz Pipeline Development
2w ago
Creative Medical Technology Holdings Announces Positive Initial Safety, Tolerability, and Efficacy Data from First Cohort in Phase 1/2 Trial of CELZ-201-DDT for Chronic Back Pain
3w ago